The U.S. Food and Drug Administration (FDA) has approved a new injectable form of Opdivo® (nivolumab). This gives cancer patients a faster and easier way to receive immunotherapy treatment. The original form of Opdivo is given through an intravenous infusion (IV). The new version is a single shot into the muscle, like a flu shot.
This change could help people with mesothelioma, who often have to go through long, complex treatments. With this approval, the cancer community moves closer to more patient-friendly care. Keep reading to see how this update could affect the patient experience for mesothelioma.
What Is Opdivo?
Opdivo is a type of immunotherapy known as a checkpoint inhibitor. It works by helping the immune system detect and fight cancer cells.
Doctors often use Opdivo alongside another drug called Yervoy® (ipilimumab). This drug combination is common for people with pleural mesothelioma. It is often given to patients who aren’t eligible for surgery.
Key Details About the FDA Approval of Injectable Opdivo
The FDA approved the injectable version of Opdivo in March 2025. It is approved for the same types of patients as the IV form of Opdivo. The drug itself hasn’t changed, just the way it’s administered. In the future, patients may be able to get this shot at their local cancer clinic—or even at home.
The new version:
- Is given as a single shot into the muscle, typically the thigh or upper arm
- Takes less than 5 minutes to administer
The FDA’s approval is based on clinical trial results. In the study, the shot delivered the same amount of medicine into the blood as the IV version. It also seemed to be as effective at keeping tumors from progressing.
What to Consider About Injectable Opdivo
This version of Opdivo is not a new drug or treatment plan. It is a different way of delivering the same medication, but it may not be suitable for everyone. Only a doctor can decide if a patient should switch from IV to injectable Opdivo.
Research into Opdivo and other immunotherapy drugs is ongoing. Further improvements are still possible.
What Does This Mean for Mesothelioma Patients?
People with mesothelioma often face physically and emotionally draining treatment schedules. Reducing the time spent in hospitals or infusion centers could make a big difference. The injectable form of Opdivo can help support that goal.
It may provide:
- Greater access to treatment: This option may benefit people in rural or underserved areas. Clinics that can’t give IV infusions might still be able to give injections. That could make it easier for patients to get recommended treatments.
- Improved comfort: An injection is quicker and less involved than an IV. It can make appointments faster and less stressful. This may help people who have trouble sitting or traveling for long periods.
- Improved quality of life: Easier access and shorter visits may allow patients to focus more on daily life than on their next treatment. It could also help improve the treatment experience.
The approval of injectable Opdivo is a small but important step forward in mesothelioma care. It reflects a growing focus on comfort, convenience and patient-centered treatment. If this option sounds helpful, ask your doctor if it’s right for you.
